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Abstract
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus 
(HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not rec-
ommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent 
monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation 
of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum con-
centration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following 
the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available 
literature regarding tenofovir-based nephrotoxicity.
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Introduction
Combined anti-retroviral treatment (cART) regimens for 
human immunodeficiency virus (HIV) and hepatitis B virus 
(HBV) infection are often formulated for patients with nor-
mal renal function, and finding suitable regimes for patients 
whose renal function has deteriorated can be challenging. 
Tenofovir disoproxil fumarate (TDF), a nucleotide reverse 
transcriptase inhibitor (NRTI), has been extensively used 
as a ‘backbone’ for such treatment, with more than 50% 
of patients on a TDF-based regimen. TDF is a prodrug, 
being converted intracellularly to tenofovir diphosphate, a 
structural analogue of deoxyadenosine triphosphate which 
suppresses viral replication by inhibiting viral reverse tran-
scriptase (1). However, TDF has been associated with the 
development of a progressive, predominantly proximal, tu-
bulopathy with renal impairment in a small number of pa-
tients (2). Frequent renal function testing has been advocated 
to detect this complication (3), and proximal tubulopathy 
may be detected by looking for evidence of metabolic acido-
sis, hypophosphatemia, hyperphosphaturia, hypokalaemia, 
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hyperuricaemia, tubular proteinuria, aminoaciduria and gly-
cosuria. Urinary tubular markers are expensive and difficult 
to monitor; therefore, tubular proteinuria may be inferred by 
the ratio of urinary albumin (conveniently measured by urine 
albumin to creatinine ratio (uACR) on a spot sample) com-
pared with urinary total protein (measured with urine pro-
tein to creatinine ratio [uPCR]) (4). Thus, uACR/uPCR is a 
simple way to monitor tubular dysfunction in patients with 
HIV, with a urine albumin to protein ratio (uAPR) of ~0.4 
or less suggesting tubular proteinuria (5). However, for pa-
tients with creatinine clearance <50 ml/min, TDF is not rec-
ommended by prescribing guidelines, and if  used should be 
dose reduced. However, finding a suitable regimen to switch 
to in such patients may be tricky due to the side effects of al-
ternative medications or preexisting antiretroviral resistance. 
Tenofovir alafenamide (TAF), another prodrug of tenofovir, 
which is preferentially concentrated in lymphoid tissue, offers 
an improved renal safety profile and may offer a simple switch 
in patients with renal issues, where alternatives may be less de-
sirable. We report the cases of two complex patients in whom 
TDF-based therapy was associated with significant side ef-
fects, who showed clear benefit by a switch from TDF to TAF.
Case 1
A 62-year-old man diagnosed with HIV-1 infection in 1985 
was referred in 2013 for assessment of renal impairment 
and proteinuria. He was highly treatment experienced and 
previous genotypic testing had demonstrated acquired HIV 
resistance to all NRTIs except for intermediate resistance to 
emtricitabine, to all non-nucleoside RTIs, to all protease inhib-
itors except low level resistance to darunavir, and likely non- 
response to the entry inhibitor maraviroc. Nevertheless, his 
treatment regimen of TDF, emtricitabine, ritonavir-boosted 
darunavir and raltegravir kept his HIV viral load undetect-
able and CD4 count within the reference range (480 cells/µL 
[reference range 400–1500]). Other comorbidities included 
previous Hodgkin’s lymphoma diagnosed and treated in 2007 
with adriamycin, bleomycin, vincristine and dacarbazine 
from which he achieved a complete response, with no obvi-
ous immediately or long-term toxicities noted. He had type-2 
diabetes mellitus for 8 years treated with oral hypoglycaemic 
agents, cirrhosis due to non-alcoholic steatohepatitis, hyper-
lipidaemia on a statin, paroxysmal atrial flutter and treated 
hypertension. He had no family history of renal disease, did 
not consume alcohol and had given up smoking more than 
10 years ago.
His creatinine had been stable at ~110 µmol/L (MDRD ~58 
eGFR ml/min/1.73 m2) for the last 3 years, but at presentation 
his urinary protein level had begun to creep up with a urine 
protein–creatinine ratio of 110 mg/mmol and an albumin–
creatinine ratio of 40 mg/mmol. At clinic visits prior to this, 
his blood pressure had been well controlled (<140/80 mmHg). 
Most electrolytes were within reference ranges, but serum bi-
carbonate 21 mmol/L (25–35 mmol/L), corrected calcium 
2.39 mmol/L (2.1–2.6 mmol/L), magnesium 0.84 mmol/L 
(0.7–1.1) and phosphate 0.32–0.80 mmol/L (0.80–1.5). At this 
time, he was also noted to be glycosuric on dipstick with nor-
mal plasma glucose. Ultrasound showed normal renal sized 
kidneys and his autoantibodies were negative. There was no 
change in urinary protein leak in response to the addition of 
an angiotensin-converting enzyme inhibitor.
Given this patient’s previous treatment exposure, resis-
tance mutations and comorbidities, the options for alterna-
tive treatments were extremely limited. Initially, a trial of 
dose reduction of the TDF component of his therapy was 
attempted, reducing 300 mg daily to 300 mg second daily 
dosing. However, there was no significant improvement in 
Figure 1. This graph illustrates the reduction in proteinuria (uPCR), initially without much change in albuminuria (uACR) after 
starting TAF. This increases uAPR above 0.4 for the first time since the patient developed proteinuria. The significance of uAPR 
with low total urine protein is unknown and is not shown when uPCR < 30 mg/mmol shaded (as per Ref [5]).
TDF to TAF switch for tubulotoxicity
 Journal of Renal and Hepatic Disorders 2018; 2(2): 1–5 3
renal parameters including those of glomerular filtration rate 
(GFR), proteinuria, serum bicarbonate, or phosphate levels, 
but his HIV viral load remained suppressed on a lower dose 
regimen.
A switch from TDF to TAF 10 mg daily was performed, 
and he remained on emtricitabine 200 mg daily. On a TAF-
based regimen, there were significant improvements within 
a month (mean ± standard deviation) in uPCR 72 ± 26 to 
56 ± 17 mg/mmol (p < 0.05), uAPR 0.3 ± 0.06 to 0.39 ± 0.07, 
(P < 0.001), serum albumin 42 ± 3 to 44 ± 4 (P < 0.05), serum 
phosphate (0.69 ± 0.16 to 0.87 ± 0.13 mmol/L (P < 0.001) and 
serum urate (0.21 ± 0.01 to 0.26 ± 0.03; p < 0.02)  (Figure 1). 
Serum creatinine (112 ± 8 to 115 ± 10, p = ns), uACR (23 ± 10 
to 23 ± 10, p = ns) and eGFR (58 ± 5 to 55 ± 5, p = ns) re-
mained unchanged and viral load stayed undetectable with 
good CD4 counts.
Case 2
A 45-year-old man with a history of  amphetamine use 
was admitted with exertional dyspnoea, 15 kg weight loss 
and intermittent fever, but no cough or orthopnoea. Chest 
X-Ray showed bilateral pulmonary infiltrates and follow-up 
computed tomography of  the chest showed bilateral central 
ground glass changes with associated interstitial septal thick-
ening and abruptly demarcated upper lobe emphysema. An 
HIV test was positive, HIV viral load was 982, 444 copies/ml 
and CD4 count was 20 cells/µL. Pneumocystis jiroveci pneu-
monia (PJP) was confirmed at bronchoscopy in addition to 
Myocbacterium avium complex (MAC). He was treated with 
high-dose trimethoprim/ sulphamethoxazole, prednisolone, 
ethambutol, clarithromycin and rifampicin.
At admission, his creatinine was 75 µmol/L, and no pro-
teinuria was noted upon urine dipstick. His admission was 
further complicated by staphylococcal pneumonia, and cy-
tomegalovirus encephalitis treated with valganciclovir. His 
creatinine peaked at 130 µmol/L, which then normalised 
to 70 µmol/L as he recovered from his acute infection. Two 
weeks after admission he was started on TDF/emtricitabine. 
Within 1 week, his serum phosphate fell to a nadir of 0.31 
mmol/L and he required significant phosphate replacement, 
up to 100 mmol/day, in addition to diet (recommended di-
etary intake 32 mmol/day) for 2 weeks, with inability to wean. 
Fractional excretion of phosphate was 42% (normal < 20%). 
Additionally, he had a protein–creatinine ratio of 179 mg/
mmol, and an urine ACR of 9.29 mg/mmol (uAPR of 0.05). 
He was switched to TAF/emtricitabine and improvement was 
noted with his electrolytes within 1 week, with a rapid wean 
of his phosphate replacement until stabilisation of serum 
phosphate at 1.2 mmol/L within 1 week (Figure 2). One 
month following his change to TAF, his creatinine remained 
within the normal range and his levels of proteinuria fell to 
within the normal range by 3 months (PCR 28 mg/mmol) 
and by 1 year (PCR 18, ACR 1.1 mg/mmol). Phosphate levels 
have remained within the normal range on no replacement.
Discussion
An estimated 36.7 million people were living with HIV in 2016 
(6) and the increasing prevalence is mainly related to the lon-
ger life expectancy due to cART (7). Thus, an older prevalent 
population is emerging with many years of well-suppressed 
HIV who are developing more issues related to chronic disease 
such as cardiovascular disease, diabetes and chronic kidney 
Figure 2. Serum phosphate levels rise and oral phosphate replacement requirements fall significantly and acutely on change 
from TDF to TAF.
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disease (CKD). The  complex interplay between chronic viral 
infection, cART and natural ageing contributes to increased 
chronic morbidity in this population (8). Patients living with 
HIV have higher rates of CKD than the general population, 
in developed countries, and whilst specific HIV-related glom-
erular disorders (e.g. HIV-associated nephropathy or immune 
complex kidney disease) contribute to renal disease burden, 
this is becoming an increasingly rare contributor to the causes 
of kidney dysfunction (9). Tubulointerstitial disorders and 
tubulopathies are estimated to cause approximately 15% of 
renal disease in retrospective renal biopsy series (10–12). In 
a retrospective cohort single-centre study, 222 renal biop-
sies from HIV-positive patients were analysed for aetiology 
of renal impairment. One-third of biopsies were thought to 
show tubulopathy, of which ~80% were thought to be drug 
related and TDF was the main culprit. A further half  of the 
biopsies showed acute or chronic interstitial nephritis, and 
TDF was implicated in approximately one quarter of these 
(12). It should be noted that interstitial nephritis in this bi-
opsy series was also associated with opportunistic infections 
such as MAC or tuberculosis.
Current recommendations for TDF-related nephrotoxic-
ity are vague, given the absence of  strong evidence. In 2014, 
the Infectious Diseases Society of  America (IDSA) guide-
lines recommended that all patients should be screened 
regularly for blood pressure, CKD and electrolyte param-
eters at diagnosis and at the commencement of  TDF-based 
therapy (13). In the more recent Australian consensus state-
ment, it was recommended that both the urinary albumin 
and urinary protein should be measured separately to de-
tect the possible development of  tubular proteinuria (3). 
Furthermore, IDSA recommends that regimens containing 
TDF should not be commenced if  the patient has a GFR < 
60 ml/min, and to change antiretroviral therapy from TDF-
containing regimens if  there is a >25% decline in GFR or 
development of  tubular dysfunction (13). Similar recom-
mendations have been made by the European Association 
for the Study of  the Liver (14).
The pharmacokinetics of TAF make this an ideal replace-
ment for TDF as similar intracellular levels in target cells 
allow much lower levels of plasma tenofovir, and hopefully 
lower incidence of nephrotoxicity. Randomised studies of 
TAF- versus TDF-based regimes in patients with creatinine 
clearance >50 ml/min showed non-inferior efficacy in viral 
suppression and a smaller increase in creatinine and lower 
increases in urinary protein at 48 weeks (15). One single-arm 
open-label study switching patients with renal dysfunction 
(estimated creatinine clearance 30–60 ml/min) from TDF- 
to TAF-based regimes showed improvement in proteinuria 
(16). A more recent randomised control trial of TDF to TAF 
in 1443 HIV-1 patients revealed non-inferiority in terms of 
viral suppression at 96 weeks, with improvement in GFR and 
bone mineral density (17). Similar evidence in the treatment 
of Hepatitis B has emerged with again non-inferiority and 
improved renal outcomes in phase 3 trials (18, 19). In these 
cases, we observed a change in tubular proteinuria following 
the change from TDF to TAF. Case 1 was noted at referral 
to have a creatinine of approximately 110 µmol/L, which did 
not improve significantly following his change in drug regi-
men. This patient had other risk factors for preexisting reno-
vascular CKD, which would likely account for no change in 
creatinine despite change to TAF. The improvement in elec-
trolyte parameters and tubular proteinuria in both patients 
suggests that there is a degree of reversibility, which is likely 
to be more significant if  the earlier change in therapy from 
TDF to TAF is made.
The World Health Organization guidelines regarding an-
tiretroviral therapy mention caution with regard to CKD and 
suggest that TAF may be helpful in this patient group; how-
ever, the guidelines have not routinely recommended the drug 
due to lack of safety data in pregnant women (20, 21). TAF 
has been more recently approved in the USA, Europe (22) 
and recently in Australia as part of fixed-dose formulations 
in combination with emtricitabine alone or with addition of 
a third antiretroviral agent.
In summary, we show here that it appears safe and effi-
cacious to switch treatment-experienced and inexperienced 
patients with tubulopathy and renal impairment to a TAF-
based regimen. The efficacy of such a switch can be assured 
by following biochemical markers suggestive of tubular dam-
age like proteinuria, uAPR and the degree of phosphaturia.
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